Skip to main content
. Author manuscript; available in PMC: 2018 Oct 1.
Published in final edited form as: Clin Cancer Res. 2018 Jan 4;24(7):1654–1666. doi: 10.1158/1078-0432.CCR-17-2168

Figure 5. Pharmacokinetic, toxicity and efficacy studies of gemcitabine.

Figure 5

Plasma and tECF concentration-time plots in the indicated tumor types treated with 60mg/kg bolus (A) or 3 hour infusion (B) gemcitabine. C, Graphs showing induction of tumor cell apoptosis measured by cleaved Caspase 3 immunohistochemistry in mice with the indicated brain tumors treated with 60mg/kg or 3 hour infusion of gemcitabine. D, Toxicity determined by weight loss in mice treated with the indicated doses and regimens of gemcitabine (in C, D: *, p<0.05; **, p<0.005; ***, p<0.0005, Mann-Whitney), E–J, (left) bioluminescence measurement of tumor growth in mice treated with indicated dose and schedule of gemcitabine. In parenthesis are the days (d) when treated tumor volume was significantly (p<0.05, non-parametric) less than control. (Right) survival curves of the same mice shown left. P value=Log Rank relative to control.